Mongoose Bio CEO Neil Warma takes stage at the Inaugural Abu Dhabi Global Healthcare Summit
Inaugural summit brings together leading global experts to discuss strategies for accelerating the future of Global Healthcare
Houston, Texas, May 13, 2024 – Mongoose Bio, a clinical-stage biopharmaceutical company revolutionizing T-cell-based therapies for solid cancers, announced today that its President and CEO, Neil Warma, will be an esteemed speaker at the inaugural Abu Dhabi Global Healthcare Summit. The summit, held from May 13-15, 2024, will convene global healthcare leaders to strategize the future of healthcare innovation and accessibility.
Mr. Warma will be speaking on a panel on the topic: Targeted Immunotherapies: Pioneering a Brighter Future for Cancer Treatment, which takes place on the mainstage on May 13 from 12.40-13.20 PM
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, the Abu Dhabi Global Healthcare Summit is a groundbreaking initiative organized by the Abu Dhabi Department of Health (DoH). Focused on transforming global healthcare systems, the event emphasizes sustainability and the shift from treatment to prevention.
Abu Dhabi Global Healthcare Week is expected to bring together over 5,000 attendees, 100 exhibitors, 200 expert speakers and 1,000 conference delegates. The event comes at a pivotal time for the global healthcare sector as the industry strives to establish a stronger, accessible, interconnected system.
“I am honored to join distinguished leaders at this landmark event to discuss the transformative potential of targeted immunotherapies,” said Mr. Warma. “As the industry advances toward more personalized and effective cancer treatments, Mongoose Bio is proud to contribute to a future where solid tumor therapies offer improved outcomes for patients worldwide.”
About Mongoose Bio
Mongoose Bio is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge cellular immunotherapies for solid cancers. Leveraging proprietary technologies such as the Immunopeptidome Discovery Platform (IDP) and Epigenetic T Cell Reprogramming (ECMR), Mongoose Bio is at the forefront of next-generation TCR-T therapies. Learn more at www.mongoosebio.com.
Forward Looking Statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. These statements reflect the company’s current expectations regarding future events, including, but not limited to clinical development timelines, regulatory approvals, and commercial potential. Actual results could differ materially due to factors such as scientific, clinical, operational, or financial challenges. The company undertakes no obligation to update these statements except as required by law.
Investor Relation & Media Contact:
Email: info@mongoosebio.com